Tech Regulation & Antitrust · Europe's 6-8 year bio-solution registration vs 6 months in Singapore creates competitive disadvantage

episode briefing

extracted intelligence

In Good Company with Nicolai Tangen

Ester Baiget - CEO of Novonesis | Podcast | In Good Company | Norges Bank Investment Management

now viewing▶ 10:30

Europe's 6-8 year bio-solution registration vs 6 months in Singapore creates competitive disadvantage

2025-11-12 · 2 company · 5 thematic

sentiment

2 bull0 bear0 neu

speakers

ester baiget

CEO of Novonesis (merged Chr. Hansen and Novozymes), previously spent 25 years at DSM in chemicals. Chemical engineer with MBA, Spanish/Catalan leading a Danish-headquartered global bio-solutions company. Focused on replacing fossil-based chemicals with nature-based alternatives via enzymes and microbes.

nicolai tangen

Nicolai Tangen is the CEO of Norges Bank Investment Management, which manages the Norwegian Sovereign Wealth Fund, one of the world's largest sovereign wealth funds. He hosts the podcast 'In Good Company' where he interviews leaders across various fields.

now playing · Tech Regulation & Antitrust

AI Drug Discoverytailwindscore 9/10ester baiget

AI cuts industrial enzyme design from 1 year to seconds using proprietary 100K strain library

Novonesis leverages its library of 100,000+ documented microbial strains linked to field performance data to train AI models that predict protein structures in seconds versus one year of la…

Advanced Manufacturingtailwindscore 8/10ester baiget

Bio-solutions target $1T specialty chemicals market with 8% CO2 reduction potential

Industrial biotechnology can replace fossil-based chemicals across a $1T specialty chemicals market, potentially reducing global CO2 emissions by 8% and generating $800B economic profit by…

Public Markets & Valuationtailwindscore 7/10ester baiget

Foundation ownership enables 37% EBITDA margins and decade-long R&D horizons

Novo Nordisk Foundation's controlling stake allows Novonesis to maintain 10% revenue R&D investment, accept 37% EBITDA margins, and make decade-long capacity decisions without quarterly pre…

Tech Regulation & Antitrustheadwindscore 7/10ester baiget

Europe's 6-8 year bio-solution registration vs 6 months in Singapore creates competitive disadvantage

Regulatory frameworks designed for fossil-based chemicals delay bio-solution deployment: Europe takes 6-8 years to register a microbe for fertilizer replacement versus 2 years in Brazil and…

Advanced Manufacturingtailwindscore 6/10ester baiget

Enzymatic PET depolymerization enables infinite recycling but requires value chain build-out

Enzymes can break PET into monomers for infinite recycling with lower energy, but commercialization depends on external milestones: collection infrastructure, processing plants, and regulat…